July 14, 2025

One-Year Outcomes of “off-label” Transcatheter Devices in Native Aortic Regurgitations

View Full Paper

Ask AI

Bookmark

The study assessed the safety and feasibility of off-label TAVR devices in patients with aortic regurgitation.
Outcomes such as 1-year all-cause mortality and major adverse events were similar between AR and AS groups.
A total of 445 patients were treated, with 177 excluded due to severe comorbidities.
The research shows the potential of off-label TAVR devices to improve left ventricular function, especially in AR patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Retrospective analysis shows similar 1-year mortality and adverse events in AR and AS patients, suggesting off-label TAVR is feasible.

Tang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark